Rhygaze is a Biotech company based in Basel, Switzerland. It has raised $97M in total funding. Latest round: Series A.
Rhygaze funding overview
Rhygaze is a Biotech company based in Basel, Switzerland. Rhygaze has raised $97M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in December 2024. The round record for Rhygaze runs through 2024; nothing later has been disclosed. Investors on record include GV, ARCH Venture Partners, F-Prime Capital, BioGeneration Ventures, Novartis Venture Fund. 5 distinct backers are named across the disclosed rounds.
Rhygaze has raised $97M in total disclosed funding across the rounds on record.
Who has invested in Rhygaze?
GV, ARCH Venture Partners, F-Prime Capital, BioGeneration Ventures, Novartis Venture Fund are named among the investors backing Rhygaze.
What was the latest Rhygaze funding round?
The most recent disclosed round is a Series A, announced in December 2024.
Where is Rhygaze based?
Rhygaze is based in Basel, Switzerland.
What sector does Rhygaze operate in?
Rhygaze is tracked under Biotech from Basel, Switzerland, with $97M in disclosed funding.
When did Rhygaze last raise?
The last disclosed Rhygaze round closed in December 2024 at Series A.
Totals shown for Rhygaze aggregate every disclosed round on file. To see how that compares, browse the Biotech companies in Basel and the investors behind them below.
